What is Welchol (Colesevelam)?
Welchol (colesevelam hydrochloride) is a non-absorbed bile acid sequestrant polymer used primarily to lower LDL cholesterol in patients with primary hyperlipidemia and to improve glycemic control in adults with type 2 diabetes. 1
Mechanism of Action
Colesevelam works through two distinct mechanisms depending on the clinical indication:
For Lipid Lowering
- Binds bile acids in the intestine, preventing their reabsorption
- This depletes the hepatic bile acid pool, triggering upregulation of cholesterol 7-α-hydroxylase
- Increases conversion of cholesterol to bile acids, creating increased demand for cholesterol in liver cells
- Results in dual compensatory effects: increased HMG-CoA reductase activity and increased hepatic LDL receptor expression
- Net effect: Enhanced LDL particle clearance from blood, reducing serum LDL-C by 15% as monotherapy 2, 1
For Glucose Control
The mechanism for glycemic improvement remains unknown, though it may involve TGR5 activation and increased GLP-1 secretion with primarily hepatic effects 1, 3
FDA-Approved Indications
Colesevelam is approved for three specific uses 2:
- Primary hyperlipidemia: As adjunct to diet and exercise to reduce LDL-C in adults
- Type 2 diabetes: To improve glycemic control in adults (unique among bile acid sequestrants)
- Pediatric heterozygous familial hypercholesterolemia (HeFH): For boys and post-menarchal girls aged 10-17 years who cannot reach LDL-C targets after adequate diet therapy
Dosing and Administration
Tablets: 6 tablets (3.75 g) once daily OR 3 tablets twice daily, taken with meals and liquid
Oral suspension: One 3.75-g packet once daily OR one 1.875-g packet twice daily, mixed with 4-8 ounces of water, fruit juice, or diet soft drinks; must be taken with meals 2, 1
Clinical Efficacy
Lipid Effects
- Monotherapy: 15% LDL-C reduction with 6 tablets daily
- Combination with statins: Additional 10-16% LDL-C reduction beyond statin alone 2, 4
- When combined with fenofibrate, provides additive LDL-C lowering in mixed hyperlipidemia 4
Glycemic Effects
- Reduces HbA1c by approximately 0.5% when added to metformin, sulfonylureas, or insulin 5
- Lowers both basal and postprandial glucose levels 5
Critical Contraindications
Absolute contraindications 2:
- Triglycerides >500 mg/dL
- History of hypertriglyceridemia-induced pancreatitis
- Bowel obstruction
Important Warnings and Drug Interactions
Key Precautions
- May increase triglycerides and cause acute pancreatitis—monitor TG levels closely 2
- Risk of GI obstruction—avoid in gastroparesis, GI motility disorders, or history of major GI surgery 2
- Can cause vitamin K and fat-soluble vitamin deficiencies 2
Drug-Drug Interactions
Critical timing requirement: The following medications should be administered at least 4 hours BEFORE colesevelam 2:
- Cyclosporine
- Oral contraceptives (ethinyl estradiol/norethindrone)
- Olmesartan
- Phenytoin (narrow therapeutic index)
- Sulfonylureas (glimepiride, glipizide, glyburide)
- Levothyroxine
- Warfarin (monitor INR frequently during initiation)
Common Adverse Effects
- Constipation, dyspepsia, and nausea are the predominant side effects 2
- Notably better tolerated than older bile acid sequestrants (cholestyramine, colestipol) with fewer GI complaints and better compliance rates (93%) 6, 7
Pregnancy and Special Populations
- Considered safe in pregnancy and lactation as it is not systemically absorbed 2, 1
- No dose adjustments needed in hepatic impairment 1
- Safe in mild-to-moderate renal insufficiency; not studied in severe renal impairment (CrCl <30 mL/min) 1
- Oral suspension recommended for pediatric patients due to tablet size 1
Clinical Positioning
Colesevelam represents a well-tolerated, non-systemic alternative or addition to statin therapy for LDL-C lowering, with the unique advantage of also improving glycemic control in type 2 diabetes 2. Its lack of systemic absorption makes it particularly suitable for patients who cannot tolerate statins, pregnant women, or those requiring combination lipid therapy to reach treatment goals 8, 9.
Important caveat: While colesevelam has cardiovascular outcomes data from the older cholestyramine trials showing mortality benefit, colesevelam itself has not been studied in dedicated cardiovascular outcomes trials 2.